O9387
Oxatomide
≥99%
别名:
1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C27H30N4O
CAS Number:
分子量:
426.55
EC 号:
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥99%
表单
powder
颜色
white
溶解性
DMSO: soluble
ethanol: soluble
创始人
Johnson & Johnson
SMILES字符串
O=C1Nc2ccccc2N1CCCN3CCN(CC3)C(c4ccccc4)c5ccccc5
InChI
1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
InChI key
BAINIUMDFURPJM-UHFFFAOYSA-N
基因信息
human ... DRD3(1814)
一般描述
Oxatomide, a histamine H1-receptor antagonist, is bound at high levels to plasma proteins in human blood.
生化/生理作用
Oxatomide is an anti-allergy compound. It suppresses platelet activating factor (PAF)-induced bronchoconstriction and inhibits leukotriene production.
Oxatomide, found in several antihistamines, can suppress mast cell degranulation. It can be used as an alternative to individuals with allergic rhinitis who do not or poorly respond to more established antihistamines. Oxatomide exhibits both antihistamine and anti-inflammatory properties. It exhibits therapeutic effects against asthma and vulvar lichen sclerosus.
特点和优势
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Yong-Soo Park et al.
The Laryngoscope, 116(9), 1642-1646 (2006-09-07)
Inflammatory mediators (IMs) play a major role in the production of middle ear effusion (MEE). Tumor necrosis factor (TNF)-alpha and leukotrienes (LTs) appear to be important in the pathogenesis of otitis media with effusion (OME). The purpose of this study
D M Richards et al.
Drugs, 27(3), 210-231 (1984-03-01)
Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in
Gunnar M Buyse et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 11(6), 337-340 (2007-04-27)
The authors report a pilot open-label two-center therapeutic trial of oxatomide in 14 steroid-naive DMD boys aged 5-10 years. Comparison of linear evolutions between 3 months medication-free lead-in periods and 6 months treatment periods showed no significant differences in quantitative
Drug eruption and liver injury caused by terfenadine and oxatomide.
Takayuki Suyama et al.
European journal of dermatology : EJD, 12(4), 385-386 (2002-07-04)
C Dani et al.
Drugs under experimental and clinical research, 28(5), 207-210 (2003-03-15)
The pharmacokinetics and tolerability of oxatomide oral suspension were investigated in preterm infants to evaluate the feasibility of planning a further study to assess its antiinflammatory effects and its effectiveness in preventing chronic lung disease (CLD). Following the administration of
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持